Metformin use in type 2 diabetic patients is not associated with lower arterial stiffness

Citation for published version (APA):
Metformin use in type 2 diabetic patients is not associated with lower arterial stiffness: the Maastricht Study


Introduction: Type 2 diabetes (T2D) is associated with cardiovascular disease complications such as myocardial infarction and stroke. These complications are at least partially the consequence of diabetes-associated increased arterial stiffness. Metformin, a first choice oral glucose-lowering drug, has been associated with potential cardio-protective effects. However, there are no data on the association between real-life metformin use and arterial stiffness. The objective of the current study is to investigate in a population-based sample of individuals with T2D the association between metformin use and arterial stiffness (i.e. carotid–femoral pulse wave velocity, cfPWV) and carotid stiffness [i.e. carotid distensibility coefficient and Young’s elastic modulus (YEM)].

Methods: We used data from The Maastricht Study, an ongoing observational prospective population-based cohort study (current \( N = 3451 \)). All participants with T2D, based on pharmacy records (\( N = 672, 31.3% \) women, mean age 62.6 ± 7.7), were included in the current study. Linear regression analyses were used to study the association between current metformin use and cfPWV, distensibility coefficient and YEM, as compared with no metformin use. Furthermore, metformin use was stratified by cumulative dose (in grams), continuous duration of use (in days), average daily dose (in grams) and time since first prescription (in years). Regression coefficients of distensibility coefficient were multiplied by −1, consequently, for all arterial stiffness indices, a positive regression coefficient signifies increasing arterial stiffness.

Results: Linear regression showed that neither current metformin use was associated with cfPWV [adjusted \( B: -0.04 (-0.11 \text{ to } 0.02) \)] nor metformin use was as stratified by cumulative dose, by continuous duration of use, by average daily dose or by time since first prescription. Metformin use was statistically significantly associated with higher carotid stiffness as assessed by distensibility coefficient [0.12 (0.01 to 0.23)], but not with YEM [0.10 (−0.03 to 0.22)]. However, there was no consistent pattern with the different stratifications of metformin use when further investigating the association with distensibility coefficient.

Conclusion: We showed that there is no significant association between current metformin use and arterial stiffness, regardless of how metformin use in itself was defined. In addition, metformin use was not associated with a lower carotid stiffness. The present results showed no beneficial effect of metformin use, dosage or duration on arterial stiffness in middle-aged patients with T2D. Alternatively, metformin may exert its cardio-protective effects via other pathways.

Keywords: carotid artery, distensibility, metformin use, pulse wave velocity

Abbreviations: AGE, advanced glycation end-product; ATC, anatomical therapeutical chemical; cfPWV, carotid–femoral pulse wave velocity; CVD, cardiovascular disease; DDD, defined daily dosage; HbA1c, glycated haemoglobin; MAP, mean arterial pressure; T2D, type 2 diabetes; YEM, Young’s elastic modulus
INTRODUCTION

In the year 2030, 439 million individuals will suffer from type 2 diabetes (T2D), which will be followed by an epidemic of related cardiovascular disease (CVD) complications such as myocardial infarction (MI) and stroke [1]. These complications are, at least partially, the consequence of increased arterial stiffness [2–4]; as increased arterial stiffness ultimately leads to increased SBP and decreased DBP, which hampers coronary perfusion and increases the pulsatile pressure load on the cerebral (micro-)circulation [5].

The oral glucose-lowering drug metformin is a first choice therapeutic agent in the treatment of T2D [6]. Interestingly, it has been suggested that metformin use may protect against CVD. One pathway via which metformin use may reduce CVD is via an effect on arterial stiffness [7–12].

Alternatively, it has been suggested that metformin may interfere with endothelial dysfunction, chronic low-grade inflammation and/or increased oxidative stress [6,15]. These phenomena are all associated with increased arterial stiffness. Currently, there are no data in the population at large on the association between metformin use and arterial stiffness, including both aortic and carotid stiffness.

In view of the above, we set out to investigate in a population-based sample of individuals with T2D the association between metformin use and aortic stiffness (i.e. carotid–femoral pulse wave velocity, cfPWV) and carotid stiffness [i.e. carotid distensibility coefficient and Young’s elastic modulus (YEM)]. Metformin use (yes versus no) was defined according to cumulative dose (in grams), continuous duration of use (in days), average daily dose (in grams) and time since first prescription (in years). We compared metformin use with nonuse.

METHODS

We used data from The Maastricht Study, an observational prospective population-based cohort study. The rationale and methodology have been described elsewhere [16]. In brief, the study focuses on the cause, pathophysiology, complications and comorbidities of T2D and is characterized by an extensive phenotyping approach. Eligible for participation were all individuals aged between 40 and 75 years and living in the southern part of the Netherlands. Participants were recruited through mass media campaigns and from the municipal registries and the regional Diabetes Patient Registry via mailings. Recruitment was stratified according to known T2D status, with an oversampling of individuals with T2D, for reasons of efficiency.

To investigate the association between metformin use and arterial stiffness we included all participants with T2D, enrolled between November 2010 and September 2013, and for whom pharmacy data was available (N = 672). Pharmacy data were available up to the date of the first visit at the Maastricht Study. Participants were classified as having T2D if they had a dispensing of an antihyperglycemic drug [anatomical therapeutical chemical (ATC) A10 [17]] in the 6 months before the first visit (patients with type 1 diabetes mellitus were excluded). Based on the pharmacy dispensing data patients were classified as a current metformin or nonmetformin user. Current metformin users were initially selected as having at least one metformin dispensing in 6 months prior to the first study visit according to pharmacy dispensing records.

The examinations of each participant were performed within a time window of 3 months. The cfPWV measurements were performed during the second visit, which was for the majority of the patients within 8–14 days after their first visit. The study has been approved by the institutional medical ethical committee (NL31329.068.10) and the Minister of Health, Welfare and Sports of the Netherlands (Permit 131088-105234-PG). All participants gave written informed consent.

Pharmacy dispensing records

Dispensing records were collected at 25 loco-regional pharmacies for all participants who gave written informed consent for the collection of their drug dispensing history. Dispensing data (available from 1 January 1991) contained product name, ATC code [17], amount and date dispensed, and the prescribed dosage regimen. For current metformin users all prescriptions before the first study visit were extracted. For every prescription, the total amount of defined daily dosage (DDD) was calculated. If the DDD could not be calculated the median DDD was assigned (0.07% of the prescriptions). The cumulative dose was estimated by adding all prescribed doses of metformin (in DDDS). The average daily dose was determined as the cumulative amount of DDDS divided by the time between the first metformin prescription and the date of the study visit. To determine the continuous duration of use we calculated the expected end date for every metformin prescription by dividing the total number of prescribed tablets over the number of tablets prescribed per day and adding this to the dispensing date. When the expected end date could not be estimated the median duration was added to determine the expected end date. A gap of 30 days between the estimated end date of a prescription and the date of the next prescription was allowed for a prescription to count as continuous use [18]. Continuous duration of use was then defined as the time between the first prescription that fulfilled this criteria and the date of the first study visit.

Arterial stiffness measurements

All measurements were done by trained vascular technicians unaware of the participants’ clinical or diabetes status, in a dark, quiet temperature controlled room (21–23°C). Participants were asked to refrain from smoking and drinking coffee or tea or alcoholic beverages 3 h prior to the study. Participants were allowed to have a light meal [breakfast and/or lunch]. All measurements were performed in supine position after 10 min of rest. Talking or sleeping was not allowed during the examination. During the vascular measurements (approximately 45 min), brachial systolic, diastolic,
and mean arterial pressure (MAP) were determined every 5 min with an oscillometric device (Accutorr Plus; Datascopc Inc., Montvale, New Jersey, USA). A three-lead ECG was recorded continuously during the measurements to facilitate automatic signal processing.

**Carotid-to-femoral pulse wave velocity**

cfPWV was determined according to recent guidelines [19] with the use of applanation tonometry (SphygmoCor; Atcgor Medical, Sydney, Australia). Pressure waveforms were determined at the right common carotid and right common femoral arteries. Difference in the time of pulse arrival from the R-wave of the ECG between the two sites (transit time) was determined with the intersecting tangents algorithm. The pulse wave travel distance was calculated as 80% of the direct straight distance (measured with an infantometer) between the two arterial sites. The median of three consecutive cfPWV (defined as travelled distance/transit time) recordings was used in the analyses.

**Local arterial elastic properties**

Measurements were done at the left common carotid (10 mm proximal to the carotid bulb), the right common femoral (10–20 mm proximal to the flow divider) and the right brachial (20 mm proximal to the antecubital fossa) arteries, with the use of an ultrasound scanner equipped with a 7.5-MHz linear probe (MyLab 70; Esaote Europe B.V., Maastricht, The Netherlands). This setup enables the measurement of diameter, distension and intima–media thickness (IMT) as described previously [20,21]. Briefly, during the ultrasound measurements a B-mode image on the basis of 19 M-lines was depicted on screen and an online echo-tracking algorithm showed real-time anterior and posterior arterial wall displacements. The M-mode recordings were composed of 19 simultaneous recordings at a frame rate of 498 Hz. The distance between the M-line recording positions was 0.96 mm, thus, a total segment of 18.24 mm of each artery was covered by the scan plane. For offline processing, the radiofrequency signal was fed into a dedicated personal computer-based acquisition system (ART.LAB; Esaote Europe B.V.) with a sampling frequency of 50 MHz. Data processing was performed in MatLab (version 7.5; Mathworks, Natick, Massachusetts, USA). The distension waveforms were obtained from the radio frequency data with the use of a wall track algorithm [20]. Carotid IMT was defined as the distance of the posterior wall from the leading edge interface between lumen and intima to the leading edge interface between media and adventitia [21]. The median diameter, distension and IMT of three measurements were used in the analyses. Local arterial elastic properties were quantified by calculating the following indices [22]:

1. **Distensibility coefficient (DC)**
   \[
   DC = \frac{2(\Delta D \times D + \Delta D^2)}{(PP \times D^2)} \quad (10^{-3} \text{ kPa}^{-1})
   \]

2. **Young’s elastic modulus (YEM) (carotid artery only)**
   \[
   YEM = \frac{D}{(\text{IMT} \times \text{DC})} \quad (10^3 \text{ kPa})
   \]

where \( D \) is arterial diameter; \( \Delta D \) distension; IMT intima–media thickness; and PP brachial pulse pressure (calculated as SBP – DBP).

Distensibility coefficient represents arterial stiffness; YEM, the stiffness of the arterial wall material at operating pressure. Note that higher values of cfPWV and YEM, but lower values of distensibility coefficient reflect greater arterial stiffness. To make the interpretation of the different indices comparable, the regression coefficients in our models (below) of distensibility coefficient were multiplied by −1. Therefore, for all arterial stiffness indices, a positive regression coefficient signifies increasing arterial stiffness.

**Reproducibility**

Reproducibility was assessed in 12 individuals (six men; 60.8 ± 6.8 years; six T2D) who were examined by two observers at two occasions spaced 1 week apart. The intraobserver and interobserver intraclass correlation coefficients were for cfPWV 0.87 and 0.69, respectively; for carotid distensibility coefficient 0.85 and 0.73, respectively; and for YEM 0.72 and 0.71, respectively.

**Covariates**

Weight and height were measured without shoes and wearing light clothing using a scale and stadiometer to the nearest 0.5 kg or 0.1 cm (Seca, Hamburg, Germany). BMI was calculated by dividing the weight in kilogram by the height in meters squared. CVD history, smoking status and diabetes duration were assessed by questionnaire. Participants were regarded as having a history of CVD if they reported to have had a MI, and/or cerebrovascular infarction or haemorrhage, and/or percutaneous artery angioplasty of/or vascular surgery on the coronary, abdominal, peripheral or carotid arteries. Use of lipid-modifying and antihypertensive medication was assessed during a medication interview where generic name, dose and frequency were registered. Insulin use in the 6 months before the first visit was determined based on the pharmacy dispensing data using ATC code [17] A10A. Glycated haemoglobin A1c (HbA1c), total and HDL cholesterol and triglycerides were determined as described elsewhere [16]. Glomerular filtration rate was estimated according to the Chronic Kidney Disease Epidemiology Collaboration equation based on the combination of serum creatinine and serum cystatin C [23]. Office blood pressure (BP) was determined using a noninvasive BP measurement device (Omron 705IT; Omron, Kyoto, Japan). MAP was calculated using the office BP measurements and defined as: \( \frac{(\text{SBP} + 2 \times \text{DBP})}{3} \).

**Statistical analysis**

Linear regression analyses were used to study the associations between metformin use and cfPWV, distensibility coefficient and YEM, as compared with nonmetformin use. All arterial stiffness indices were log transformed because of skewed distributions. Metformin use was stratified according to cumulative dose, continuous duration of use, average daily dose and time since first prescription.

We first adjusted the models for age and sex (covariates of model 1). In model 2, the following covariates were
added: MAP, BMI, smoking, history of CVD, use of antihypertensive medication and use of lipid modifying drugs. Moreover, HbA1c, diabetes duration, and use of insulin were added to adjust for severity of diabetes.

In addition, two sensitivity analyses were performed. First, we restricted the main analysis to patients with a cPWV more than 10.0. As those patients are expected to have more vascular alterations which may affect the results.

In the second, sensitivity analysis we further adjusted the main analysis for BP control, defined as an office BP less than 140/90 mmHg.

Furthermore, we compared our cPWV data with the published BP corrected age-matched reference data [24].

A P value less than 0.05 was considered statistically significant. All analyses were done with SAS 9.4 (SAS Institute Inc., Cary, North Carolina, USA).

RESULTS
In total 672 participants with T2D and pharmacy dispensing data were available for the current analyses. Due to missing values on covariates 43 patients were excluded (missing data on BMI (n = 2), smoking (n = 26), history of CVD (n = 38), use of antihypertensive medication (n = 1), use of lipid-modifying drugs (n = 1) and HbA1c (n = 2). These missing data were not mutually exclusive. Furthermore, when studying cPWV, 122 participants were excluded due to missing values for cPWV (due to logistic or technical reasons) which resulted in a study population of 507 participants (453 metformin users and 54 nonmetformin users). Data from 530 participants was available when studying distensibility coefficient and data from 529 participants when investigating YEM.

In Table 1, the baseline characteristics of the study population are shown. Metformin users were less often women (29.4 and 40.7%, respectively), used more often lipid-modifying drugs (82.8 versus 70.4%) and had on average a shorter duration of diabetes (5.6 versus 7.4 years) as compared with nonmetformin users.

Metformin use and carotid-to-femoral pulse wave velocity
After adjustment for age and sex (covariates of model 1), MAP, BMI, smoking, prior CVD, the use of antihypertensive medication, the use of lipid-modifying medication, HbA1c, diabetes duration and current insulin use (extra covariates in model 2), metformin use was not statistically significantly associated with lower aortic stiffness, as estimated by cPWV [regression coefficient (B) and 95% confidence interval: −0.04 (−0.11 to 0.02); Table 2, row metformin use (nonmetformin use is reference category)].

If we analysed metformin use according to cumulative dose in grams (categories >0–1023, 1024–3121 and ≥3122) the results showed that, after adjustment for the covariates of model 2, aortic stiffness, as estimated by cPWV, was not statistically associated with the different categories of cumulative metformin dose Table 2, row cumulative dose).

Similar results were obtained if metformin use was analysed according to continuous duration of use (in days), average daily dose (in grams) or time since first prescription (in years).

| Table 1. Baseline characteristics of current metformin and nonmetformin users |
|-----------------------------|-----------------------------|
|                             | Nonmetformin users, N = 54  | Metformin users, N = 453 |
| Age, years                  | 62.5 ± 8.0                  | 62.6 ± 7.4 |
| Sex (women)                 | 20 (40.7)                   | 133 (29.4) |
| BMI (kg/m^2)                | 29.0 ± 4.2                  | 29.5 ± 4.6 |
| <25 kg/m^2                  | 13 (24.1)                   | 71 (15.7)  |
| ≥25–30 kg/m^2               | 19 (35.2)                   | 193 (42.6) |
| ≥30 kg/m^2                  | 22 (40.7)                   | 189 (41.7) |
| Smoking status              |                             |                |
| Never                       | 13 (24.1)                   | 127 (28.0)   |
| Former                      | 29 (53.7)                   | 258 (57.0)   |
| Current                     | 12 (22.2)                   | 68 (15.0)    |
| History of cardiovascular disease | 17 (31.5)                 | 121 (26.7)   |
| Use of lipid-modifying drugs | 38 (70.4)                   | 375 (82.8)   |
| Use of antihypertensive drugs | 40 (74.1)                 | 334 (73.7)   |
| eGFR (ml/min per 1.73 m^2)  | 81.4 ± 21.4                 | 85.3 ± 17.1  |
| Total cholesterol to HDL ratio | 3.8 ± 1.3                  | 3.6 ± 1.1    |
| Triglycerides (mmol/l)      | 1.8 ± 1.3                   | 1.7 ± 0.9    |
| HbA1c (%)                   | 7.7 ± 1.2                   | 7.0 ± 1.0    |
| Glucose (mg/dl)             | 112.7 ± 20.8                | 112.2 ± 16.8 |
| office SBP (mmHg)           | 142.7 ± 21.8                | 142.2 ± 16.8 |
| Office DBP (mmHg)           | 75.4 ± 11.8                 | 77.2 ± 9.4   |
| Office heart rate           | 70.2 ± 12.3                 | 72.6 ± 11.9  |
| cPWV (m/s)                  | 10.6 ± 2.5                  | 9.9 ± 2.3    |
| DC (10^-5 kPa^-1)           | 14.4 ± 4.9                  | 13.1 ± 4.9   |
| YEM (10^-5 kPa)             | 0.7 ± 0.3                   | 0.8 ± 0.4    |

Data are presented as number (%) of patients or mean ± SD. cPWV, carotid–femoral pulse wave velocity; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin A1c.

aBased on the CKDEPI formula, and 452 observations (50 nonmetformin users and 402 metformin users).
bBased on office SBP and DBP measurements.
cBased on 530 observations in total (57 nonmetformin users and 473 metformin users).
dBased on 529 observations in total (57 nonmetformin users and 472 metformin users).

Metformin use and carotid stiffness indices
After adjustment for age and sex (covariates of model 1) and MAP, BMI, smoking, prior CVD, use of antihypertensive medication, and/or use of lipid-modifying medication, HbA1c, diabetes duration, and current insulin use (extra covariates of model 2) metformin use was statistically significantly associated with higher carotid stiffness as estimated by distensibility coefficient [0.12 (0.01–0.23); recall −1 multiplication], but not with YEM [0.10 (−0.05 to 0.22)] (Table 3, row metformin use (nonmetformin use is reference category)).

If we analysed metformin use according to cumulative dose in grams (categories >0–1023, 1024–3121 and ≥3122) the results showed that, after the adjustments for the covariates of model 2, carotid stiffness as estimated by distensibility coefficient and YEM was associated with greater stiffness for some of the cumulative dose categories, whereas there was no association with the highest cumulative dose category.

If we analysed metformin use according to continuous duration of use in days (categories 0–90, 91–547 and ≥548), the results showed that, after the adjustments for the covariates of model 2, carotid stiffness as estimated by distensibility coefficient and YEM did not decrease with a longer period of continuous use.
If we analysed metformin use according to average daily dose in grams (categories ≤1.0, 1.01–1.80 and ≥1.81), the results showed that, after the adjustments for the covariates of model 2, all average daily dose categories were statistically significantly associated with greater carotid stiffness as estimated by distensibility coefficient [0.13 (0.02–0.25), 0.14 (0.03–0.26), 0.15 (0.04–0.27)] but not with YEM; (Table 3; row average daily dose).

Finally, if we analysed metformin use according to time since first prescription in years (categories <3.0, 3.0–4.9 and ≥5.0) the results showed that, after adjustment for the covariates of model 2, carotid stiffness, as estimated by distensibility coefficient and YEM, did not decrease with a longer time since the first prescription.

### Sensitivity analyses
Restricting our analysis to participants with a cPWV more than 10.0 did not substantially change the results [cPWV: 0.01 (−0.05 to 0.05), distensibility coefficient: 0.12 (−0.28 to 0.02), YEM: 0.11 (−0.06 to 0.28)]. Adjusting the main

### TABLE 3. Current metformin use and carotid artery stiffness indices

<table>
<thead>
<tr>
<th>Carotid artery distensibility coefficient</th>
<th>N = 530</th>
<th>Model 1 β (95% CI)</th>
<th>Model 2 β (95% CI)</th>
<th>Carotid artery young’s elastic modulus</th>
<th>N = 529</th>
<th>Model 1 B (95% CI)</th>
<th>Model 2 B (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metformin use</td>
<td>57</td>
<td>Reference</td>
<td>Reference</td>
<td>57</td>
<td>Reference</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>No current metformin use</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current metformin use</td>
<td>473</td>
<td>0.12 (0.01 to 0.22)*</td>
<td>0.12 (0.01 to 0.23)*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>By cumulative dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–1023 g</td>
<td>158</td>
<td>0.13 (0.02 to 0.24)*</td>
<td>0.18 (0.06 to 0.30)*</td>
<td></td>
<td>159</td>
<td>0.10 (−0.02 to 0.22)</td>
<td>0.16 (0.02 to 0.29)*</td>
</tr>
<tr>
<td>1024–3121 g</td>
<td>156</td>
<td>0.12 (0.02 to 0.23)*</td>
<td>0.16 (0.05 to 0.27)*</td>
<td></td>
<td>155</td>
<td>0.13 (0.01 to 0.25)*</td>
<td>0.16 (0.03 to 0.29)*</td>
</tr>
<tr>
<td>≥3122 g</td>
<td>159</td>
<td>0.11 (−0.00 to 0.22)</td>
<td>0.11 (−0.00 to 0.22)</td>
<td></td>
<td>159</td>
<td>0.06 (−0.06 to 0.19)</td>
<td>0.06 (−0.07 to 0.18)</td>
</tr>
<tr>
<td>By continuous duration of use</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–90 days</td>
<td>146</td>
<td>0.11 (0.00 to 0.22)*</td>
<td>0.14 (0.03 to 0.26)</td>
<td></td>
<td>146</td>
<td>0.09 (−0.03 to 0.21)</td>
<td>0.11 (−0.02 to 0.24)</td>
</tr>
<tr>
<td>91–547 days</td>
<td>172</td>
<td>0.17 (0.06 to 0.28)*</td>
<td>0.21 (0.10 to 0.32)*</td>
<td></td>
<td>172</td>
<td>0.16 (0.04 to 0.28)*</td>
<td>0.19 (0.06 to 0.31)*</td>
</tr>
<tr>
<td>≥548 days</td>
<td>155</td>
<td>0.07 (−0.04 to 0.18)</td>
<td>0.09 (−0.02 to 0.20)</td>
<td></td>
<td>154</td>
<td>0.05 (−0.07 to 0.17)</td>
<td>0.06 (−0.06 to 0.19)</td>
</tr>
<tr>
<td>By average daily dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1.0 g/day</td>
<td>161</td>
<td>0.11 (−0.00 to 0.21)</td>
<td>0.13 (0.02 to 0.25)*</td>
<td></td>
<td>166</td>
<td>0.09 (−0.03 to 0.21)</td>
<td>0.10 (−0.02 to 0.23)</td>
</tr>
<tr>
<td>1.01–1.80 g/day</td>
<td>154</td>
<td>0.11 (0.00 to 0.22)*</td>
<td>0.14 (0.03 to 0.26)*</td>
<td></td>
<td>153</td>
<td>0.09 (−0.03 to 0.22)</td>
<td>0.12 (−0.01 to 0.25)*</td>
</tr>
<tr>
<td>≥1.81 g/day</td>
<td>153</td>
<td>0.14 (0.04 to 0.25)*</td>
<td>0.15 (0.04 to 0.27)*</td>
<td></td>
<td>153</td>
<td>0.12 (−0.00 to 0.24)</td>
<td>0.12 (−0.01 to 0.25)*</td>
</tr>
<tr>
<td>By time since first metformin prescription</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;3.0 years</td>
<td>154</td>
<td>0.12 (0.01 to 0.23)*</td>
<td>0.16 (0.04 to 0.28)*</td>
<td></td>
<td>154</td>
<td>0.11 (−0.01 to 0.23)</td>
<td>0.15 (0.01 to 0.29)</td>
</tr>
<tr>
<td>3.0–4.9 years</td>
<td>121</td>
<td>0.08 (−0.03 to 0.19)</td>
<td>0.11 (−0.02 to 0.23)</td>
<td></td>
<td>120</td>
<td>0.06 (−0.06 to 0.19)</td>
<td>0.09 (−0.05 to 0.22)</td>
</tr>
<tr>
<td>≥5.0 years</td>
<td>198</td>
<td>0.15 (0.04 to 0.25)*</td>
<td>0.15 (0.04 to 0.26)*</td>
<td></td>
<td>198</td>
<td>0.11 (−0.00 to 0.23)</td>
<td>0.11 (−0.02 to 0.23)</td>
</tr>
</tbody>
</table>

CI, confidence interval. Model 1: adjusted for age and sex. Model 2: adjusted for model 1, mean arterial pressure, BMI, smoking, history of cardiovascular disease, use of antihypertensive medication, use of lipid-modifying medication and glycated haemoglobin A1c, diabetes duration and current use of insulin.

*aRegression coefficients of carotid artery distensibility coefficient are multiplied by −1, therefore, for all carotid stiffness indices, a positive regression coefficient signifies increasing stiffness.

*Statistically significant, P value less than 0.05.
analysis for BP control did not materially change the results (cfPWV: −0.04 (−0.10 to 0.03), distensibility coefficient: 0.14 (0.04 to 0.25), YEM: 0.12 (−0.00 to 0.23)).

Comparison with reference data
At an individual level the majority (97.8%) of the patients had a cfPWV which was in the BP corrected age-matched range (mean ± 2SD) of the reference values [26]. The other patients had a cfPWV higher than the BP corrected age-matched range.

DISCUSSION
The results of the current study show that there is no association between current metformin use and aortic stiffness as estimated by cfPWV, regardless of how metformin use was further defined (e.g. by cumulative dose, average daily dose, continuous duration of use or time since first prescription). In addition, use of metformin was not associated with a decrease in carotid stiffness as assessed by distensibility coefficient and YEM. Counter intuitively, some individual categories of the metformin exposure were associated with greater stiffness, however no consistent pattern with the different stratifications of metformin use was found. Thereby the results of the current study do not support the hypothesis that metformin use protects against CVD by lowering arterial stiffness.

To the best of our knowledge there is currently no population-based data available on the association between use of metformin and arterial stiffness. Interestingly, our population-based data are in line with small (n ≤ 52) clinical trials, which studied short-term use (<52 weeks) of metformin and various arterial stiffness parameters and showed no effect [25,26].

Our study population was characterized by good glycaemic control (mean HbA1c 7.0) and well controlled hypertension (73.9% of participants used antihypertensive drugs). As high BP is a prime determinant of arterial stiffness, the fact that our population was well treated might have caused an underestimation of the associations between metformin use and arterial stiffness. In addition, the majority of our study population had a cfPWV which was in the BP corrected age-matched range. It may be suggested that as a result of this there are only relatively few vascular alterations in our study population, which may be a reason why we did not found an association between use of metformin and arterial stiffness.

One of the hypothesized mechanisms how metformin might decrease arterial stiffness includes via its effect on AGEs. It has been suggested that metformin might reduce the AGEs via its antioxidative properties. Metformin treatment (100, 250 and 500 μmol/l) reduced intracellular reactive oxygen species in human aortic endothelial cells [27]. In addition, use of metformin (60 mg/kg/day) has been associated with a reduced production of superoxide and a reduced level of Nε-(carboxymethyl)lysine, one of the AGEs, in diabetic rats [28]. Both studies investigated metformin concentrations which do not occur in clinical practice (peak concentration is about 15 μmol/l in humans [29]). This observation leaves room to speculate whether animal and in-vitro results could be directly translated to T2D patients.

An alternative explanation for the fact that we did not find an association between use of metformin and cfPWV might be selection bias or confounding by disease severity. Study participation is voluntary, and it might therefore be that only relatively healthy patients with T2D, who are potentially intensively treated for cardiovascular risk factors, participated (selection bias). Yet, 26.4% of the metformin users still had a history of CVD. Disease severity may have been an important confounder in this study, as patients with a poor glycaemic control are often prescribed higher dosages of metformin and these patients might also have more arterial stiffness as a consequence of the poor glycaemic control. We tried to capture disease severity in our analyses by adjusting for duration of diabetes, use of insulin, and HbA1c. These adjustments only slightly changed the point estimates, suggesting that confounding by disease severity was not an issue in the current study.

Strengths of this study include the availability of longitudinal data on metformin prescriptions, which permitted us to reliably estimate the average and cumulative dose as well as the continuous duration of metformin use. In addition, this made it possible to study long-term use of metformin and to test our hypothesis in different ways. Moreover, we have been able to adjust for different important confounders. Limitations of this study include a relatively small sample size, which may be the reason we failed to show an association. Furthermore, only cross-sectional data were available on the arterial stiffness parameters, which makes it impossible to examine causal relationships at this stage.

We showed that dosage and duration of metformin were not associated with aortic stiffness as measured by cfPWV. In addition, we showed that metformin dosage and duration were not associated with lower carotid stiffness as measured by distensibility coefficient and YEM. The present results showed no beneficial effect of metformin dosage or duration on arterial stiffness in middle-aged patients with T2D using metformin as compared with nonmetformin users. Alternatively, metformin may exerts its cardio-protective effects via other pathways, for example, via its beneficial effects on endothelial dysfunction and(or) low-grade inflammation [30].

ACKNOWLEDGEMENTS
We thank all participants of the Maastricht Study, their community pharmacist and the Apothekers Vereniging Maastricht for their cooperation.

The current study was supported by the European Regional Development Fund via OP-Zuid, the Province of Limburg, the Dutch Ministry of Economic Affairs (grant 31O.041), Stichting De Weijerhorst (Maastricht, the Netherlands), the Pearl String Initiative Diabetes (Amsterdam, the Netherlands), the Cardiovascular Center (CVC, Maastricht, the Netherlands), Cardiovascular Research Institute Maastricht (CARIM, Maastricht, the Netherlands), School for Public Health and Primary Care (CAPHRI, Maastricht, the Netherlands), School for Nutrition, Toxicology and Metabolism (NUTRIM, Maastricht, the Netherlands),
Stichting Annadal (Maastricht, the Netherlands), Health Foundation Limburg (Maastricht, the Netherlands) and by unrestricted grants from Janssen-Cilag B.V. ( Tilburg, the Netherlands), Novo Nordisk Farma B.V. ( Alphen aan den Rijn, the Netherlands) and Sanofi-Aventis Netherland B.V. (Gouda, the Netherlands).

Conflicts of interest
J.D., H.O., M.S., C.V.K., K.R., S.S., C.S., N.S., A.K., C.S., R.H. declare no conflicts of interest. F.d.V reports that he supervises a PhD student who is employed at Roche Pharmaceuticals. He has not received any fees or reimbursement for this. J.v.B. reports grants and personal fees from Eli Lilly, grants and personal fees from Amsgen, grants from Will Pharma, outside the submitted work.

REFERENCES

Metformin use and arterial stiffness in type 2 diabetics

22. Reneman RS, Meinders JM, Hoeks AP. Noninvasive ultrasound in arterial wall dynamics in humans: what we have learned and what remains to be solved. Eur Heart J 2005; 26:960–966.